PareshDandonaMDPhysician

Endocrinology • Buffalo, NY

Distinguished Professor, Head Division of Endocrinology, State University of New York at Buffalo

Join to view full profile

Dr. Dandona is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Dandona's full profile

Already have an account?

Office
3 Gates Cir
Diabetes Center Of Wny
Buffalo, NY 14209
Phone+1 716-887-4069

Fax+1 716-626-7990
Is this information wrong?

Education & Training

All India Institute of Medical SciencesClass of 1965

Certifications & Licensure

NY State Medical License 1994 - 2026

Awards, Honors, & Recognition

Buffalo Spree Magazine Castle Connolly, 2006, 2008, 2013-2014
Fellow (FACC) American College of Cardiology
Fellow (FACE) American Association of Clinical Endocrinology

Clinical Trials

Effect of Androgel on Type 2 Diabetic Males With Hypogonadism Start of enrollment: 2006 Jul 01
Completed
Phase 4
Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI. Start of enrollment: 2007 Feb 01
Terminated
Phase 4
Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism Start of enrollment: 2007 Jun 01
Terminated
Not Applicable
The Effect of Januvia (Sitagliptin) on Oxidative Stress in Obese Type 2 Diabetic Subjects Start of enrollment: 2008 Mar 01
Completed
Not Applicable
Testosterone Replacement in Men With Diabetes and Obesity Start of enrollment: 2010 May 01
Completed
Phase 4
The Suppression of Toll Like Receptors by Insulin Start of enrollment: 2008 Sep 01
Completed
Not Applicable
Exeantide in Type 2 Diabetes on Insulin Start of enrollment: 2008 Apr 01
Completed
Phase 2
Resveratrol in Type2 Diabetes and Obesity Start of enrollment: 2008 Dec 01
Terminated
Not Applicable
Effect of Pioglitazone on Oxidative Load, Inflammatory End-Points and Vascular Reactivity in Obese Non-Diabetic Patients: A Dose Ranging Study
Completed
Phase 4
Liraglutide as Additional Treatment in Patients With Type 1 Diabetes Mellitus Start of enrollment: 2010 Oct 01
Completed
Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 Diabetes Start of enrollment: 2012 Nov 01
Withdrawn
Phase 3
Liraglutide in Type 1 Diabetes Start of enrollment: 2012 Nov 01
Completed
Phase 3
Liraglutide in the Treatment of Type 1 Diabetes Mellitus Start of enrollment: 2012 Nov 01
Completed
Phase 3
Sitagliptin in Type I Diabetic Patients Start of enrollment: 2011 Jun 01
Withdrawn
Not Applicable
Liraglutide In Overweight Patients With Type 1 Diabetes Start of enrollment: 2012 Dec 01
Completed
Phase 3
An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin Start of enrollment: 2015 Nov 01
Completed
Phase 4
Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes Start of enrollment: 2016 Mar 01
Completed
Not Applicable
An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes Start of enrollment: 2016 Nov 01
Completed
Not Applicable
GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes Start of enrollment: 2017 Jan 10
Terminated
Phase 4
Triple Therapy in T1DM Start of enrollment: 2019 May 01
Recruiting
Phase 2, Phase 3
Anti-inflammatory Effects of the Fiber Start of enrollment: 2016 Jun 14
Unknown status
Not Applicable
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Glucagon-like peptide-1 receptor agonists as a possible intervention to delay the onset of type 1 diabetes: A new horizon.
Nassar, M., Ajay Chaudhuri, Husam Ghanim, Paresh Dandona, Mahmoud Nassar> ;World Journal of Diabetes. 2024 Feb 15
2 citations
Semaglutide in Early Type 1 Diabetes.
Paresh Dandona, Ajay Chaudhuri, Husam Ghanim> ;The New England Journal of Medicine. 2023 Sep 7
Vasoactive mediators of hypertension in obesity.
Husam Ghanim, Tina K Thethi, Sanaa Abuaysheh, Vivian Fonseca, Paresh Dandona> ;American Journal of Physiology. Endocrinology and Metabolism. 2023 Oct 1
6 citations
Omega-3 Fatty Acids in Cardiovascular Disease and Diabetes: a Review of Recent Evidence.
Salman Bhat, Sudipa Sarkar, Paresh Dandona, Rita R Kalyani, Zaffar, D.> ;Current Cardiology Reports. 2023 Feb 1
2 citations
Insulin Resistance and Glycated Hemoglobin in Obesity Are Associated With Preference for Sugar-Sweetened Yogurt: A Pilot Study.
Leonard H Epstein, Mathew J Biondolillo, Ashfique Rizwan, Husam Ghanim, Paresh Dandona, Warren K Bickel, Rocco A Paluch> ;Psychosomatic Medicine. 2023 Apr 1
10 citations
Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance.
J David Spence, Catherine Viscoli, Walter N Kernan, Lawrence H Young, Karen Furie, Ralph DeFronzo, Muhammad Abdul-Ghani, Paresh Dandona, Silvio E Inzucchi> ;Diabetes, Obesity & Metabolism. 2022 Jun 1
6 citations
High prevalence of subnormal testosterone in obese adolescent males: reversal with bariatric surgery.
Sandeep Dhindsa, Husam Ghanim, Todd Jenkins, Thomas H Inge, Carroll M Harmon, Amit Ghoshal, Zengru Wu, Michael J McPhaul, Farid Saad, Paresh Dandona> ;European Journal of Endocrinology. 2022 Feb 1
Recognizing the True Value of Testosterone Therapy in Health Care.
Abraham Morgentaler, Abdulmaged Traish, Rajat S Barua, Paresh Dandona, Sandeep Dhindsa, Mohit Khera, Farid Saad> ;Androgens. 2022 Jan 1
Hypogonadotropic Hypogonadism in Diabesity: Pathogenic Factors and Therapeutic Implications.
Paresh Dandona, Sandeep Dhindsa, Husam Ghanim> ;Androgens. 2022 Jan 1
5 citations
4-Phenylbutyric acid improves free fatty acid-induced hepatic insulin resistance in vivo.
Sandra Pereira, Jessy Moore, Jia-Xu Li, Wen Qin Yu, Husam Ghanim, Filip Vlavcheski, Yemisi Deborah Joseph, Paresh Dandona, Allen Volchuk, Carolyn L. Cummins, Evangelia...> ;Endocrine Connections. 2021 Jul 28
5 citations
Diabetes, Obesity, COVID-19, Insulin, and Other Antidiabetes Drugs.
Paresh Dandona, Husam Ghanim> ;Diabetes Care. 2021 Jul 7
5 citations
The side effects of immune checkpoint inhibitor therapy on the endocrine system.
Itivrita Goyal, Manu Raj Pandey, Rajeev Sharma, Ajay Chaudhuri, Paresh Dandona> ;The Indian Journal of Medical Research. 2021 Apr 1
12 citations
Dapagliflozin reduces systolic blood pressure and modulates vasoactive factors
Husam Ghanim, Manav Batra, Kelly Green, Jeanne Hejna, Sanaa Abuaysheh, Antione Makdissi, Ajay Chaudhuri, Paresh Dandona> ;Diabetes, Obesity & Metabolism. 2021 Jul 1
20 citations
Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and -2 studies
Moshe Phillip, Chantal Mathieu, Marcus Lind, Eiichi Araki, Paolo Di Bartolo, Richard M. Bergenstal, Simon Heller, Lars Hansen, Markus F. Scheerer, Fredrik Thoren, Niki...> ;Diabetes, Obesity & Metabolism. 2021 Feb 1
29 citations
Mechanisms underlying the metabolic actions of testosterone in humans: A narrative review.
Paresh Dandona, Sandeep Dhindsa, Husam Ghanim, Farid Saad> ;Diabetes, Obesity & Metabolism. 2021 Jan 1
38 citations
Remission of type 2 diabetes following long-term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11-year data fro...
Karim Sultan Haider, Ahmad Haider, Farid Saad, Gheorghe Doros, Markolf Hanefeld, Sandeep Dhindsa, Paresh Dandona, Abdulmaged M. Traish> ;Diabetes, Obesity & Metabolism. 2020 Nov 1
21 citations
Benefit/risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m2.
Chantal Mathieu, Paresh Dandona, Andreas L. Birkenfeld, Troels Krarup Hansen, Nayyar Iqbal, John Xu, Enrico Repetto, Markus F. Scheerer, Fredrik Thoren, Moshe Phillip> ;Diabetes, Obesity & Metabolism. 2020 Nov 1
31 citations
Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials.
Per-Henrik Groop, Paresh Dandona, Moshe Phillip, Pieter Gillard, Steven V. Edelman, Johan Jendle, John Xu, Markus F. Scheerer, Fredrik Thoren, Nayyar Iqbal, Enrico Rep...> ;The Lancet. Diabetes & Endocrinology. 2020 Oct 1
23 citations
Liraglutide treatment in overweight and obese patients with type 1 diabetes: A 26-week randomized controlled trial; mechanisms of weight loss.
Husam Ghanim, Manav Batra, Kelly Green, Sanaa Abuaysheh, Jeanne Hejna, Antione Makdissi, Robert Borowski, Nitesh D. Kuhadiya, Ajay Chaudhuri, Paresh Dandona> ;Diabetes, Obesity & Metabolism. 2020 Oct 1
Effective Initiation and Treatment With Basal Insulin in People With Type 2 Diabetes: Focus on Mitigating Hypoglycemia in Patients at Increased Risk: Executive Summary.
John E. Anderson, Scott Urquhart, Geralyn R. Spollett, Paresh Dandona> ;Clinical Diabetes. 2020 Oct 1
30 citations
Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized control...
Chantal Mathieu, Gottfried Rudofsky, Moshe Phillip, Eiichi Araki, Marcus Lind, Niki Arya, Fredrik Thoren, Markus F. Scheerer, Nayyar Iqbal, Paresh Dandona> ;Diabetes, Obesity & Metabolism. 2020 Sep 1
1 citations
Narcolepsy, depression, and severe flushing in an obese man.
Fatimo Biobaku, Adel Hanna, George Matthews, Sandeep Dhindsa, Paresh Dandona> ;Clinical Case Reports. 2020 Aug 10
20 citations
Bariatric Surgery: Remission of Inflammation, Cardiometabolic Benefits, and Common Adverse Effects.
Fatimo Biobaku, Husam Ghanim, Scott V Monte, Joseph A. Caruana, Paresh Dandona> ;Journal of the Endocrine Society. 2020 Aug 4
6 citations
Semaglutide in Cystic Fibrosis-Related Diabetes
Helen Prathiba Gnanapragasam, Naghma Mustafa, Mary Bierbrauer, Tara Andrea Providence, Paresh Dandona> ;The Journal of Clinical Endocrinology and Metabolism. 2020 Jul 1
13 citations
Adjunct Therapies in Treatment of Type 1 Diabetes
Itivrita Goyal, Alamgir Sattar, Megan Johnson, Paresh Dandona> ;Journal of Diabetes. 2020 Jun 21
Join now to see all

Journal Articles

Hypogonadotropic Hypogonadism in Men with Diabesity
Sandeep Dhindsa, Paresh Dandona, Diabetes Care

Lectures

New Treatments for Type 1 Diabetes and the Pathophysiology of Microvascular Complications
ENDO 2019 - New Orleans, LA - 3/24/2019

Press Mentions

Deficiency That Affects Nearly 40% of Men over 45 May Double Risk of Severe Covid - StudySeptember 10th, 2022
Low Testosterone May Raise Risk of COVID HospitalizationSeptember 9th, 2022
Blood Compound ‘Lac-Fe’ May Help Treat Obesity, Study SuggestsJune 21st, 2022
Join now to see all

Grant Support

Testosterone Effects On Insulin Sensitivity &Inflammation In T2dm And ObesityNational Institute Of Diabetes And Digestive And Kidney Diseases2011
Hypogonadotropic Hypogonadism, Insulin Sensitivity And Inflammation In Type 2 DIANational Institute Of Diabetes And Digestive And Kidney Diseases2009–2010
Inflammation In Obesity: Modulation By Weight LossNational Institute Of Diabetes And Digestive And Kidney Diseases2005–2009